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Background: Short and long-acting beta2-agonists (SABA and LABA) have a crucial role in
asthma management during pregnancy, as stated in the current guidelines.
Objective: To systematically review the evidence on beta2-agonists use during pregnancy and
adverse perinatal outcomes.
Data sources and study selection: Six databases were searched before January 1, 2013 for beta2-
agonists use during pregnancy and congenital malformations, small for gestational age, mean and
low birth weight, gestational age and preterm delivery. Original English language articles were
includedwithnocut-off date.Quality assessmentandpost-hocpower calculationswereperformed.
Results: Twenty-one original studies were identified. Four studies reported a significant increased
risk of congenital malformations with SABA, while one study reported a significant decreased risk
with highdoses of SABA.One study reported a significant increased risk of congenitalmalformations
with LABA and four studies reported a significant increased risk of congenital malformations with
beta2-agonists (SABA and/or LABA). One study reported a decrease in birth weight centiles among
LABA users.
Limitations: All studies reporting significant results, except two, used non-asthmatic women as
reference group, making it difficult to differentiate between the effect of the disease from the
one of the beta2-agonists. Non-significant results should be interpreted with caution due to the
low statistical power of several studies.
Conclusion: Methodological limitations and lack of power of several studies prevent us to conclude
on the perinatal safety of beta2-agonists. Until further evidence is available, physicians should
continue prescribing them as recommended in the guidelines whenever needed to attain asthma
control.
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Asthma is considered to be one of the most common
chronic diseases among pregnant women, affecting
approximately 4e8% of the pregnancies in the United
States and even higher among other populations [1e3].
Pregnant women with severe or uncontrolled asthma are at
higher risk for pregnancy complications and adverse fetal
outcomes than women with well-controlled asthma
[2,4e8]. Due to the reported potential risk of uncontrolled
asthma during pregnancy on the health of the mother and
fetus, the National Asthma Education and Prevention Pro-
gram (NAEPP) states that “(.) it is safer for pregnant
women with asthma to be treated with asthma medica-
tions than it is for them to have asthma symptoms and
exacerbations.” [2]
While inhaled corticosteroids (ICS) are considered the
cornerstone therapy in the management of persistent
asthma during pregnancy [9,10], beta2-agonists have a
crucial role in asthma management [2]. During pregnancy,
short-acting beta2-agonists (SABA) are used as reliever
medications for all asthma types (mild, moderate, or se-
vere), while long-acting beta2-agonists (LABA) are used in
cases of moderate to severe persistent asthma, in combi-
nation with low or medium doses ofICS [2,11]. It has been
reported that 40e70% of asthmatic women use SABA and
8e13% use LABA during pregnancy [12,13]. Despite being
widely used during pregnancy, all of the SABA and LABA are
classified as “C” under the US Food and Drug Administration
(FDA) categorization [4], which states that risk cannot be
ruled out and that there is a chance of fetal harm if the
drug is administered during pregnancy, but the potentialbenefits may outweigh the potential risk. Moreover, the
Teratogen Information System (TERIS) reports that SABA
and LABA have an “Undetermined” teratogenic risk due to
the limited quality and quantity of data on the safety of
these medications [4].
Several studies examined the effect of SABA and LABA
use on perinatal outcomes during pregnancy [2,14e24].
Published reviews on this topic did not capture the whole
evidence from all published studies on all clinically impor-
tant perinatal outcomes [4,14e16,25,26]. Given the need
to better estimate their fetal risks, we aimed to summarize
the existing human data e from experimental trials and
observational studies e examining the impact of the use of
inhaled SABA and LABA for the treatment of asthma during
pregnancy on several perinatal outcomes, which are major
and any congenital malformations, small for gestational age
(SGA; weight 10th percentile for the gestational age),
birth weight, low birth weight (LBW; weight <2500 g),
gestational age and preterm delivery. We also assessed the
quality of each study using a validated quality assessment
scale and performed post-hoc power calculations to eval-
uate the capacity of the studies to detect clinically rele-
vant effects.Methods
Data sources and search strategy
A search strategy was formed, registered and published
(PROSPERO 2011: CRD42011001554, http://www.crd.york.
ac.uk/PROSPERO/display_record.asp?
Beta2-agonists and perinatal outcomes 11IDZCRD42011001554). PubMed, Ovid MEDLINE, EMBASE,
Cochrane Library, Web of Science, and CINAHL were
searched for original articles. The first search was per-
formed using the keywords “asthma*” and “pregnan*”. A
second search was done using the keywords “congenital”,
“malformations”, “congenital anomalies”, “birth weight”,
“low birth weight”, “small for gestational age”, “gesta-
tional age”, “preterm delivery”, “preterm birth”, “em-
bryonic development”, “fetal development” and “foetal
development”, combined with “asthma*” and “pregnan*”.
A third search was conducted using keywords “beta-
agonist”, “short-acting beta-agonist”, “long-acting beta-
agonist” and the individual medication names [salbutamol,
albuterol, terbutaline, metaproterenol, fenoterol, salme-
terol, and formoterol], together with “asthma*” and
“pregnan*”. Furthermore, we applied a cross-search using
the keywords in the three searches. A Medical Subject
Heading (MeSH) search was also conducted in MEDLINE,
using the terms “asthma” and “pregnancy”. Human studies
published in English language were only considered in our
final selection and no particular cut-off for the date of
publication was used. Only original articles were included
and abstracts without supporting articles were excluded.
No exclusion criteria were imposed on either the choice of
the reference groups or the treatments compared to beta2-
agonists. All types of studies (RCTs, caseecontrol and
cohort studies) were searched except case-reports, case-
series and Prescription-Event Monitoring studies (PEM). All
inhaled beta2-agonists were included either taken sepa-
rately or in combination with ICS. The latest search was
performed on January 1, 2013. Related articles and data
cited in the reference book “Drugs in Pregnancy and
Lactation: A Reference Guide to Fetal and Neonatal Risk”
[17] were also included. Bibliographies of all retained ar-
ticles and reviews on the topic were searched for additional
relevant articles.Data extraction and study selection
The search strategy, including the inclusion and exclusion
criteria, is summarized in Fig. 1. We chose seven outcomes
that we believe best represent the fetal development
(major and any malformations, SGA, mean and low birth
weight) and the newborn prematurity (gestational age and
preterm delivery) among asthmatic women treated with
beta2-agonists. The primary search was conducted by one
author (SE), while a second confirmatory independent
search was performed by a second author (FZK). All studies
identified in the search were independently reviewed by
two co-authors and the study selection was made inde-
pendently by two co-authors (SE and FZK). Data extraction,
quality assessment and post-hoc power calculations
were first performed by one author (SE). An independent
data extraction and power calculation were performed by a
second author (FZK). Discrepancies were resolved by
consensus.
Data retrieved from each study included the
study reference, the design, the source of data, the
timing of exposure, the type of beta2-agonists, the defi-
nition of the reference group, the sample size of the
exposed and unexposed groups, the reported proportionsor means and standard deviations for the outcomes
in the exposed and unexposed groups, the effect
size (crude or adjusted relative risk [RR], odds ratio [OR],
or mean difference [MD]), and the p-value or 95% confi-
dence interval (CI) associated with the effect size. In
studies that did not report the effect size, a crude RR,
OR, or MD was calculated when sufficient information was
provided.
Quality assessment and power calculation
The Newcastle-Ottawa Scale for observational studies
(NOS-scale) was used for assessing the methodological
quality of studies that passed the defined inclusion criteria
[27]. We used the NOS-scale based on recommendations by
the Cochrane Non-Randomized Studies Methods Working
Group since all of the studies included were expected to be
non-randomized [28]. The NOS-scale has two forms, one for
cohort studies and one for caseecontrol studies, and
studies are being judged on three domains: (1) selection of
study groups (score: 0e4), (2) comparability of the groups
(score: 0e2), and (3) exposure/outcome ascertainment
(score: 0e3). An external reviewer was called for the
quality assessment of the study published by our group [29]
in order to avoid a conflict of interest.
We performed a post-hoc power calculation for each
study reporting non-statistically significant results to
detect a RR of 1.5, a mean difference in the birth weight of
500 g, or a mean difference in gestational age of 1 week to
establish a comparison between studies. The power calcu-
lations were based on t-tests for MD and on the test for the
difference between two independent proportions for RR
and OR. A type I error of 0.05 was used for power calcula-
tions; all calculations were performed using PASS 2008
interface of NCSS software [30].
Results
Study selection
Study selection results are summarized in Fig. 1. Using
our selection criteria, 19 original studies were found
[18e24,29,31e41]. After reviewing all cited references in
the retrieved studies, we added the data from the Collabo-
rative Perinatal Project (CPP) and the Michigan Medicaid
study (their data were retrieved from 2 books [17,42], see
Fig. 1.), having a total of 21 studies included in our review
[17e24,29,31e42]. We did not exclude any studies even if
they provided insufficient information for the power calcu-
lation. Thirteenwere cohort studies [17e21,23,24,29,33,34,
36,39,42], seven were caseecontrol studies [31,32,35,37,
38,40,41], and one was a cohort study that contained par-
tial data from a randomized controlled trial [22]. Nine
studies reported statistically significant results [24,29,31,
32,36,37,40e42]. Post-hoc power calculations were per-
formed for certain outcomes in eighteen studies [18e24,29,
31e35,37e41], while the lack of information prevented us
from performing power calculations for certain outcomes in
four studies [17,19,36,42]. Results from the quality assess-
ment of the studies using the NOS-scale are summarized in
Table 1.
PubMed
3531
articles
MEDLINE
2278
articles
Web Of
Science
1781
articles
EMBASE
2057
articles
Cochrane 
Library
91 articles
CINAHL
803
articles
7344 articles
3197 duplicate 
articles excluded
137 articles
7207 irrelevant and 
duplicate articles 
excluded
19 articles
118 articles not 
meeting inclusion 
criteria excluded
21 original studies
2 books included
aStep 1: Databases 
searched for relevant 
articles 
bStep 2: Relevant titles 
screened and further 
duplicates removed
cStep 3: Abstracts screening
dStep 4: Full texts obtained 
and references screened
Fig. 1 Strategy for the selection of the studies. aSelected databases were searched for relevant articles using defined keywords.
Articles retrieved from each database were imported into a separate EndNote library (version X4.0.1, Thomson Reuters). The six
EndNote libraries formed from the databases were combined in one large EndNote library, and duplicates between databases were
removed. bTitles were screened for relevance. Studies not related to the question of interest, animal studies, review articles, and
further duplicates were excluded at this step. cAbstracts were examined to confirm eligibility to the final selection and full text
were revised. Articles only providing relevant data on beta2-agonists and the pre-selected perinatal outcomes were included.
Published abstracts without original articles were excluded. dSelected articles were obtained and data retrieved and processed.
References were checked for additional articles and reviews on the topic were manually searched for further references.
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Major congenital malformations are defined as structural
and developmental anomalies that affect viability and/or
quality of life and require intervention [43].
Studies that investigated the association between beta2-
agonists and major congenital malformations are presented
in Table 2: six studies examined SABA and/or LABA use
[20,22,31,32,40,41], nine studies examined the SABA
separately [21,23,29,31,32,35,36,40,41], and six studies
examined LABA separately [29,32,35,36,40,41].
Among the six studies that investigated SABA and/or
LABA use, two studies used a reference group of asthmatic
pregnant women unexposed to beta2-agonists during
pregnancy; none of these two studies reported a signifi-
cant increased risk of major malformations [20,22]. Areference group of non-asthmatic or a combination of
asthmatic and non-asthmatic pregnant women has been
used in the other studies [20,31,32,40,41], with four
studies reporting a significant increased risk of major
malformations [31,32,40,41]. Indeed, Lin et al. in three
studies reported increased risk of congenital heart defects
[31] (aOR Z 2.20; 95% CI: 1.05, 4.61), gastroschisis [32]
(aOR Z 2.06; 95% CI 1.19, 3.59), and other selected
birth defects [41] (aOR Z 2.39; 95% CI 1.23, 4.66) with
beta2-agonists use during the first trimester. In a recent
caseecontrol study by Munsie et al. an association be-
tween bronchodilator use (mainly SABA and LABA) and an
increased risk of cleft lip only was found (aORZ 1.77; 95%
CI 1.08, 2.88) [40].
Among the nine studies that evaluated SABA separately,
three studies used asthmatic women unexposed to SABA
Table 1 Assessment of methodologic quality of studies according to the Newcastle-Ottawa Scale for cohort and caseecontrol
studies.
Study ref. Country Newcastle-Ottawa Scale Total score
(over 9 points)Selection
(max. 4)
Comparabilitya
(max. 2)
Exposure/outcome
(max. 3)
Cohort studies
Eltonsy et al. [29] Canada *** ** *** 8
Clark et al. [19] UK * * *** 4
Kallen et al. [36] Sweden ** * *** 6
Clifton et al. [24] Australia *** ** 5
Bakhireva et al. [20] USA **** * *** 8
Schatz et al. [22] USA **** * ** 7
Bracken et al. [18] USA *** * ** 6
Olesen et al. [39] Denmark *** ** 5
Alexander et al. [33] Canada ** * *** 6
Schatz et al. [21] USA ** * *** 6
Michigan Medicaid [17] USA ** ** 4
Lao et al. [34] Hong Kong ** ** 4
Schatz et al. [23] USA *** * *** 7
CPP[42] USA ** ** 4
Caseecontrol studies
Lin et al. [41] USA *** * ** 6
Munsie et al. [40] USA *** * ** 6
Lin et al. [31] USA **** * *** 8
Lin et al. [32] USA *** * ** 6
Tata et al. [35] UK ** * *** 6
Tamasi et al. [37] Hungary *** ** 5
Kallen et al. [38] Sweden *** * ** 6
a In rating comparability of groups, we awarded a study one star if it controlled for asthma severity/control, and another star if it
controlled for other relevant confounders.
Beta2-agonists and perinatal outcomes 13during pregnancy as the reference group [23,29,35] while
the other six studies used non-asthmatic women or the
general population as the reference group [21,31,32,
36,40,41]. In a study by Kallen et al. using the Swedish
Medical Birth Registry, the authors reported an increased
risk of any cardiac defect with salbutamol use in the first
trimester (aORZ 1.38; 95%CI 1.12, 1.70) when compared to
the general population [36]. In the study by Munsie et al.,
the authors found a significant increased risk of cleft lip
(aOR Z 1.79; 95% CI 1.07, 2.99) and cleft palate
(aOR Z 1.65; 95% CI 1.06, 2.58) with the maternal use of
salbutamol during the periconceptional period as compared
to the general population of asthmatics and non-asthmatics
[40]. In a recent study by our group, we reported a
decreased risk of major malformations with the maternal
use of high doses of SABA per week (>10 doses) as
compared to no use, with an aOR of 0.68 (95% CI 0.48, 0.95)
[29]. None of the other five studies reported a significant
association.
Regarding the six studies that examined LABA use
separately, two used a reference group of asthmatic
women unexposed to LABA [29,35]. In the study conducted
by our research group, we found a significant increased risk
of major cardiac (aORZ 2.38; 95% CI: 1.11, 5.10) and major
“other and unspecified malformations” (aOR Z 3.97; 95%
CI: 1.29, 12.20) among LABA users compared to asthmatic
non-users, but the association rendered non-significant
when all major malformations were combined together[29]. None of the other five studies reported a significant
association between LABA use and major malformations
[32,35,36,40,41].
The ten studies that reported non-significant results
for major congenital malformations and for which we
had enough information to calculate the statistical power
had a power ranging from 6% to 100% to detect an effect
size of 1.5, with only 2 studies having a power >80%
[35,41].Any congenital malformations
Congenital malformations can be defined as any structural
or functional anomalies, including metabolic disorders [43].
Any congenital malformations include all types of congen-
ital malformations (major or minor) that could occur during
fetal development.
Studies that investigated the association between beta2-
agonists use during pregnancy and any congenital malfor-
mations are presented in Table 3: four studies examined
SABA and/or LABA use [19,33,34,39], six studies examined
SABA separately [17,29,36e38,42], and four studies exam-
ined LABA separately [29,36e38]. None of the four studies
that investigated SABA and/or LABA use reported significant
results; only two studies used a reference group of asth-
matic pregnant women unexposed to beta2-agonists during
pregnancy [19,33].
Table 2 Studies investigating the association between beta2-agonists use during pregnancy and major congenital malformations.
Study ref. Design Source of data Exposure
timing
Users of b2-agonists Non-users of b2-agonists Effect Power
(%) for
RR Z
1.5
Type of b2-
agonists
n* Major
congenital
malformation
(%)
Definition n* Major
congenital
malformation
(%)
OR or
RR
95% CI
or (p-
value)
SABA and/or LABA use: cohort studies
Bakhireva
et al.
[20]
Cohort Tel. interviews
& medical
charts
Entire
pregnancy
Any 103 3.9 non-asthmatics 303 0.3 cRR 13.0 NA 8
Any 103 3.9 Asthmatics ICS
usersa
438 4.1 cRR 0.95 NA 17
Schatz
et al.
[22]
Cohort þ
RCT
Medical charts
& interviews
Entire
pregnancy
Any 1828 2.0 Asthmatics
non-usersb,c,d
295 2.0 cRR 1.0 (>0.05) 12
SABA and/or LABA use: caseecontrol studies
Study ref. Design Source of data Exposure
timing
Type of b2-
agonists
Cases Controls Definition of
non-users of
b2-agonists
Effect Power
(%) for
RR Z
1.5
Users of b2-
agonists
Non-users of
b2-agonists
Users of
b2-agonists
Non-users of
b2-agonists
OR or
RR
95% CI
or (p-
value)
Lin et al.
[41]
Case
Control
Registry,
medical
records
& self
reports
1 month prior
conception þ
1st trimester
Anyf 10 168 NA NA Asthmatics
and non-
asthmatics
non-users
aOR Z
2.39o
1.23,
4.66
NC
Munsie
et al.
[40]
Case
Control
Registry,
medical records
& self reports
1 month prior
conception þ
1st trimester
Anyf 20 570 114 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
1.77q
1.08,
2.88
NC
1 month prior
conception þ
1st trimester
Anyf 26 887 114 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
1.53r
0.99,
2.37
46
1 month prior
conception þ
1st trimester
Anyf 17 1114 114 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
0.78s
0.46,
1.31
52
2nd & 3rd
trimesters
Anyf 7 570 58 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
1.26q
0.57,
2.80
20
2nd & 3rd
trimesters
Anyf 4 887 58 6207 Asthmatics
and non-
aOR Z
0.49r
0.18,
1.36
24
14
S.
E
lto
n
sy
e
t
a
l.
asthmatics
non-users
2nd & 3rd
trimesters
Anyf 6 1114 58 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
0.59s
0.25,
1.38
27
Lin et al.
[31]
Matched
Case
Control 1:2
Registry,
medical
records & tel.
interviews
1 month prior
conception þ
1st trimester
Anyf 22 443 22 965 Asthmatics
and non-
asthmatics
with no Rx
aOR Z
2.20
1.05,
4.61
NC
Lin et al.
[32]
Case
Control
1:11
Tel. interviews
& Rx DB
1 month prior
conception þ
1st trimester
Anyg 17 358 96 3932 Asthmatics
and non-
asthmatics
non-usersg
aOR Z
2.06
1.19,
3.59
NC
SABA only: cohort studies
Study ref. Design Source of data Exposure
timing
Users of b2-
agonists
Non-users of
b2-agonists
Effect Power
(%) for
RR Z
1.5
Type of b2-
agonists
n* Major
congenital
malformation
(%)
Definition n* Major
congenital
malformation
(%)
OR or RR 95% CI
or (p-
value)
Eltonsy
et al.
[29]
Cohort Quebec
administrative
DB
1st trimester Any 7182 5.7 Asthmatics
non-usersg
5935 5.9 aOR Z
0.93
0.80,
1.08
100
Any (>0e3
doses/week)
3420 6.1 aOR Z
1.00
0.83,
1.20
99
Any (>3e10
doses/week)
2102 5.5 aOR Z
0.84
0.67,
1.06
98
Any (>10
doses/week)
1660 5.2 aOR Z
0.68
0.48,
0.95
NC
Kallen
et al. [36]
Cohort Swedish
Registers
(Medical birth,
Congenital
malformation
and Hospital
discharge)
1st trimester Salbut NA NA General
population
NA NA aOR Z
1.38h
1.12,
1.70
NC
Terbut NA NA NA NA aOR Z
1.08i
0.94,
1.23
__
Schatz
et al.
[21]
Cohort Daily diary
cards for
medications
completed by
patients.
Entire
pregnancy
Anye 667 3.7 Non-
asthmatics
823 6.2 cRR 0.60 (>0.05) 54
1st trimester Anye 488 4.3 Non-
asthmatics
1000 5.6 cRR 0.77 (>0.05) 48
(continued on next page)
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Table 2 (continued )
Study ref. Design Source of data Exposure
timing
Users of b2-agonists Non-users of b2-agonists Effect Power
(%) for
RR Z
1.5
Type of b2-
agonists
n* Major
congenital
malformation
(%)
Definition n* Major
congenital
malformation
(%)
OR or
RR
95% CI
or (p-
value)
For outcomes,
data source
not precised
Schatz
et al.
[23]
Cohort Questionnaire
for patients
identification,
confirmed
clinically þ
Self-Diary to
report use of
SABA & medical
records (for
perinatal
outcomes)
Entire
pregnancy
Anyb,f,j 259 3.9 Non-
asthmatics
295 6.4 cOR Z
0.61
(>0.05) 25
1st trimester Anyb,f,j 180 3.9 Non-
asthmatics
295 6.4 cOR Z
0.61
(>0.05) 22
Entire
pregnancy
Anyb,f,j 259 3.9 Asthmatics
non-usersg
101 6.0 cOR Z
0.65
(>0.05) 12
1st trimester Anyb,f,j 180 3.9 Asthmatics
non-usersg
172 5.3 cOR Z
0.74
(>0.05) 15
Entire
pregnancy
Anyb,f,j 259 3.5 General
population
1,999,254 3.0 cOR Z
1.17
NA 31
SABA only: caseecontrol studies
Study ref. Design Source of data Exposure
timing
Type of b2-
agonists
Cases Controls Definition of
non-users of
b2-agonists
Effect Power
(%) for
RR Z
1.5
Users of b2-
agonists
Non-users of
b2-agonists
Users of
b2-agonists
Non-users of
b2-agonists
OR or
RR
95% CI
or (p-
value)
Lin et al.
[41]
Case
Control
Registry,
medical
records
& self
reports
1 month prior
conception þ
1st trimester
Salbut 77 2776 139 6587 Asthmatics
and non-
asthmatics
non-users
cOR Z
1.31p
NA 81
Pirbuterol 3 2850 3 6723 Asthmatics
and non-
asthmatics
non-users
cOR Z
2.36p
NA 8
Munsie
et al.
[40]
Case
control
Registry,
medical
records
& self
reports
1 month prior
conception þ
1st trimester
Salbut 18 570 101 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
1.79q
1.07,
2.99
NC
1 month prior
conception þ
1st trimester
Salbut 25 887 101 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
1.65r
1.06,
2.58
NC
16
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1 month prior
conception þ
1st trimester
Salbut 15 1114 101 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
0.76s
0.44,
1.33
48
2nd & 3rd
trimesters
Salbut 7 570 55 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
1.34q
0.60,
2.98
22
2nd & 3rd
trimesters
Salbut 4 887 55 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
0.52r
0.19,
1.44
27
2nd & 3rd
trimesters
Salbut 6 1114 55 6207 Asthmatics
and non-
asthmatics
non-users
aOR Z
0.64s
0.27,
1.49
31
1 month prior
conception þ
1st trimester
Pirbuterol/
Metaprot/
Epineph
4 85 5 153 Asthmatics
and non-
asthmatics
non-users
cOR Z
1.44
NA 9
Lin et al.
[31]
Matched
Case
Control 1:2
Registry,
medical
records
& tel.
interviews
1 month prior
conception þ
1st trimester
Salbutg 15 443 14 965 Asthmatics
and non-
asthmatics
with no Rx
aOR Z
2.37
0.90,
6.23
14
1 month prior
conception þ
1st trimester
Metaprotg 1 31 1 42 Asthmatics
and non-
asthmatics
with no Rx
cRR Z
1.35
NA 6
1 month prior
conception þ
1st trimester
Terbutg 1 31 0 43 Asthmatics
and non-
asthmatics
with no Rx
__ NA __
Lin et al.
[3]
Case
Control
1:11
Tel. interviews
& Rx DB
1 month prior
conception þ
1st trimester
Salbut/
Pirbuterolg
13 368 88 4033 Asthmatics
and non-
asthmatics
non-usersg
cOR Z
1.62
NA 26
Tata
et al.
[35]
Matched
Case
Control 1:6
THIN DB Entire
pregnancy
Any 375 NA 2085 NA Asthmatics
non-usersb,c,d
aOR Z
1.06
(0.336)
0.94,
1.19
100
1st trimester NA NA NA NA NA aOR Z
1.01
(0.941)
0.86,
1.18
__
(continued on next page)
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Table 2 (continued )
Study ref. Design Source of data Exposure
timing
Users of b2-agonists Non-users of b2-agonists Effect Power
(%) for
RR Z
1.5
Type of b2-
agonists
n* Major
congenital
malformation
(%)
Definition n* Major
congenital
malformation
(%)
OR or
RR
95% CI
or (p-
value)
LABA only: cohort studies
Study ref. Design Source of data Exposure
timing
Users of b2-agonists Non-users of b2-agonists Effect Power
(%) for
RR Z
1.5
Type of b2-
agonists
n* Major
congenital
malformation
(%)
Definition n* Major
congenital
malformation
(%)
OR or
RR
95% CI
or (p-
value)
Eltonsy
et al.
[29]
Cohort Quebec
administrative
DB
1st trimester Any 165 7.9 Asthmatics
non-usersg
12,952 5.8 aOR Z
1.31
0.74,
2.31
33
4.2 2.0 aOR Z
2.38k
1.11,
5.1
NC
1.8 0.5 aOR Z
3.97l
1.29,
12.2
NC
Kallen
et al.
[36]
Cohort Swedish
Registry
(Medical birth,
Congenital
malformation
and Hospital
discharge)
1st trimester Salmeterol NA NA General
population
NA NA aOR Z
1.34m
0.96,
1.88
__
Formoterol NA NA NA NA aOR Z
1.07n
0.63,
1.82
__
LABA only: caseecontrol studies
Study ref. Design Source of data Exposure
timing
Type of b2-
agonists
Cases Controls Definition of
non-users of
b2-agonists
Effect Power
(%) for
RR Z
1.5
Users of b2-
agonists
Non-users of
b2-agonists
Users of
b2-agonists
Non-users of
b2-agonists
OR or
RR
(95% CI)
or (p-
value)
Lin et al.
[41]
Case
Control
Registry,
medical
records & self
reports
1 month prior
conception þ
1st trimester
Salmeterol 13 2840 23 6703 Asthmatics
and non-
asthmatics
non-users
cOR Z
1.33p
NA 24
18
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Munsie
et al.
[40]
Case
Control
Registry,
medical
records &
self reports
1 month prior
conception þ
1st trimester
Salmeterol 6 83 21 137 Asthmatics
and non-
asthmatics
non-users
cOR Z
0.47s
NA 23
Lin et al.
[32]
Case
Control
1:11
Tel. interviews
& Rx DB
1 month prior
conception þ
1st trimester
Salmeterolg 2 379 11 4110 Asthmatics
and non-
asthmatics
non-usersg
cOR Z
1.97
NA 7
Tata et al.
[35]
Matched
Case
Control
1:6
THIN DB Entire
pregnancy
Any 25 NA 131 NA Asthmatics
non-usersb,c,d
aOR Z
1.12
(0.614)
0.72,
1.75
49
1st trimester NA NA NA NA aOR Z
1.09
(0.77)
0.62,
1.9
__
The values in bold represent the presence of a statistically significant association.
Women participating in the different studies were asthmatic unless stated otherwise.
DB: database; ICS: inhaled corticosteroids; Salbut: Salbutamol; Isoprot: Isoproterenol; Metaprot: Metaproterenol; Terbut: Terbutaline; Epineph: Epinephrine; Ephed: Ephedrine; SABA:
Short-acting beta2-agonists; LABA: Long-acting beta2-agonists; RCT: randomized controlled trial; THIN: Health Improvement Network primary care database, Rx: prescription medications;
aOR: adjusted odds ratio; cOR: crude odds ratio; cRR: crude risk ratio; cMD: crude mean difference; aMD: adjusted mean difference; pOR :crude prevalence odds ratio; NA: data un-
available; e : power or effect size impossible to calculate; NC: statistical power not calculated since results are significant.
* Number of pregnancies unless stated otherwise.
a Women may have concurrently received short-acting beta2-agonists (inhaled or systemic).
b Women may have concurrently received inhaled corticosteroids.
c Women may have concurrently received asthma controller medications (leukotriene modifiers).
d Women may have concurrently received systemic corticosteroids (oral or intravenous).
e Women may have received inhaled, oral or injectable beta2-agonists.
f Women may have concurrently received asthma controller medications (theophylline or ipratropium).
g Women may have concurrently received any other type of asthma medication.
h The OR presented for the association between salbutamol and cardiac malformations (92 cases reported).
i The OR presented for the association between terbutaline and cardiac malformations (228 cases reported).
j Women may have concurrently received asthma controller medications (cromolyn).
k The OR presented for the association between LABA and major cardiac malformations.
l The OR presented for the association between LABA and major “other and unspecified malformations”.
m The OR presented for the association between salmeterol and cardiac malformations (35 cases reported).
n The OR presented for the association between formoterol and cardiac malformations (14 cases reported).
o The OR presented for the association between beta2-agonists and esophageal atresia.
p The OR presented for the association between beta2-agonists and selected defects including diaphragmatic hernia, esophageal atresia,
small intestinal atresia, anorectal atresia, neural tube defects, omphalocele, or limb deficiencies with no additional major defect
(isolated).
q The OR presented for the association between beta2-agonists and cleft lip only.
r The OR presented for the association between beta2-agonists and cleft palate only.
s The OR presented for the association between beta2-agonists and cleft lip with cleft palate.
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Table 3 Studies investigating the association between beta2-agonists use during pregnancy and any congenital malformations.
Study ref. Design Source of data Exposure timing Users of b2-agonists Non-users of b2-agonists Effect Power (%)
for
RR Z 1.5
Type of b2-
agonists
n* All
congenital
malformations
(%)
Definition n* All
congenital
malformations
(%)
OR or RR 95% CI or (p-
value)
SABA and/or LABA use: cohort studies
Clark et al. [19] Cohort Questionnaire &
medical charts
Entire pregnancy Any 178 2.2 Non-asthmatics 717 2.2 cRR Z 1.0a NA 16
Any 178 2.2 Asthmatics with no
Rx
370 0.8 cRR Z 2.75a NA 9
Olesen et al. [39] Cohort Registry & Rx DB 1 month prior
until 8 weeks of
pregnancy
Any 272 NA Non-users of any
Rx b
8717 NA NA (<0.05) __
Alexander et al.
[33]
Cohort Registry (perinatal
DB) & medical
charts
Not determined Any 303 8.5 Non-asthmatics 13,709 7.7 aOR Z 1.0 0.6, 1.6 58
Any 303 8.5 Asthmatics with no
Rx
375 6.9 aOR Z 0.9 0.6, 1.4 31
Any 303 8.5 Asthmatics steroid
usersc
139 6.2 aOR Z 0.8 0.4, 1.7 16
Lao et al. [34] Cohort Hospitals DB Entire
pregnancy
Anyd,e 54 3.8 Non-asthmatics 54 0.0 __ NA __
SABA only: cohort studies
Eltonsy et al. [29] Cohort Quebec
administrative DB
(medical services
and Rx DB)
1st trimester Any 7182 9.6 Asthmatics non-
usersc
5935 9.3 aOR Z 1.04 0.92, 1.17 100
Any (>0e3
week)
3420 10.0 aOR Z 1.08 0.94, 1.25 100
Any (>3e10
doses/week)
2102 9.9 aOR Z 1.07 0.90, 1.26 99
Any (>10
doses/week)
1660 8.5 aOR Z 0.90 0.74, 1.09 99
Kallen et al. [36] Cohort Swedish Registers
(Medical birth,
Congenital
malformation and
Hospital discharge)
1st trimester
(early
pregnancy,
usually 10e12
weeks)
Salbut NA NA General
population
NA NA aOR Z 1.09 0.97, 1.75 __
Terbut NA NA NA NA aOR Z 1.11 1.04, 1.19 NC
Michigan Medicaid
[17]
Cohort Surveillance
registry
1st trimester Isoprot 16 6.3f NA NA NA cRR Z 1.4 NA __
Salbut 1090 4.4f NA NA NA cRR Z 1.1 NA __
Terbut 149 4.7f NA NA NA cRR Z 1.2 NA __
Metaprot 361 4.7f NA NA NA cRR Z 1.1 NA __
Isoetharine 22 0.0f NA NA NA __ NA __
Epineph 35 0.0f NA NA NA __ NA __
CPP[42] Cohort Surveillance
registry
Early pregnancy
(1st trimester)
Isoprot 31 NA NA NA NA cRR Z 0.9 NA __
Ephed 373 NA NA NA NA cRR Z 1.1 NA __
Epineph 189 NA NA NA NA cRR Z 1.7 (<0.05) NC
SABA only: caseecontrol studies
Study ref. Design Source of data Exposure timing Type of b2-
agonists
Cases Controls Definition of
non-users of
b2-agonists
Effect Power (%)
for RR Z
1.5
Users of b2-
agonists
Non-users of
b2-agonists
Users of b2-
agonists
Non-users
of b2-
agonists
OR or RR 95% CI or (p-
value)
Tamasi et al. [37] Matched Case
control 1:3
Hungarian
registry &
questionnaire
(self-adminis
tered) þ
medical
records
Entire
pregnancy
Salbut 45 466 77 680 Asthmatics
non-users
cOR Z 0.9 0.6, 1.3 57
Terbut 179 332 241 516 cOR Z 1.2 0.9, 1.5 92
Metaprot 3 508 6 751 cOR Z 0.7 0.2, 3.0 10
Fenoterol 328 183 403 354 cOR Z 1.6 1.3, 2.0 NC
20
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Kallen et al. [38] Case control Swedish Medical
birth Register &
Interview
Early pregnancy Salbut 29 4986 3446 574,284 Asthmatics and
non-asthmatics
non-users
cOR Z 0.97
aOR Z 0.93
0.64, 1.36 70
Terbut 104 4911 10,613 567,117 cOR Z 1.13
aOR Z 1.14
0.93, 1.38 98
LABA only: cohort studies
Study ref. Design Source of data Exposure timing Users of b2-agonists Non-users
of b2-agonists
Effect Power (%)
for RR Z
1.5Type of b2-
agonists
n* All congenital
malformations
(%)
Definition n* All congenital
malformations
(%)
OR or RR 95% CI or (p-
value)
Eltonsy et al. [29] Cohort Quebec
administrative DB
(medical services
and Rx DB)
1st trimester Any 165 12.7 Asthmatics non-
usersg
12,952 9.4 aOR Z 1.37 0.92, 2.17 44
3.0 0.7 aOR Z 6.84g 2.58, 18.10 NC
3.0 0.9 aOR Z 3.43h 1.39, 8.45 NC
Kallen et al. [36] Cohort Swedish Registry
(Medical birth,
Congenital
malformation and
Hospital discharge)
1st trimester
(early
pregnancy,
usually 10e12
weeks)
Salmeterol NA NA General
population
NA NA aOR Z 1.02 0.83, 1.25 __
Formoterol NA NA NA NA aOR Z 1.06 0.80, 1.40 __
LABA only: caseecontrol studies
Study ref. Design Source of data Exposure timing Type of b2-
agonists
Cases Controls Definition of
non-users of
b2-agonists
Effect Power (%)
for RR Z
1.5
Users of b2-
agonists
Non-users of
b2-agonists
Users of b2-
agonists
Non-users
of b2-
agonists
OR or RR 95% CI or (p-
value)
Tamasi et al. [37] Matched case
control 1:3
Hungarian
registry &
questionnaire
(self-
administered)
þ medical
records
Entire pregnancy Clenbuterol 28 483 56 701 Asthmatics
non-users
cOR Z 0.7 0.5, 1.2 57
Kallen et al. [38] Case control Swedish Medical
birth Registry &
Interview
Early pregnancy Salmeterol 15 5000 1137 576,593 Asthmatics and
non-asthmatics
non-users
aOR Z 1.50 0.90, 2.53 35
The values in bold represent the presence of a statistically significant association.
Women participating in the different studies were asthmatic unless stated otherwise.
* Number of pregnancies unless stated otherwise.
a Matching was performed and not considered in crude calculations.
b Reference group formed from women who did not purchase any prescription drugs during pregnancy.
c Women may have concurrently received any other type of asthma medication.
d Women may have concurrently received inhaled corticosteroids.
e Women may have concurrently received oral asthma medication.
f Expected cases of malformations were: 0.7 case with isoproterenol, 43 with salbutamol, 6 with terbutaline, 15 with metaproterenol, 1
with isoetharine, and 1 with epinephrine.
g The OR presented for the association between LABA and any genital malformations.
h The OR presented for the association between LABA and any “other and unspecified malformations”.
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Table 4 Studies investigating the association between beta2-agonists use during pregnancy and SGA.
Study ref. Design Source of data Exposure
timing
Users of b2-agonists Non-users of b2-agonist Effect Power (%)
for RR Z
1.5
Type of b2-
agonists
n* SGA (%) Definition n* SGA (%) OR or RR 95% CI or
(p-value)
SABA and/or LABA use: cohort studies
Clark
et al.
[19]
Cohort Questionnaire
& medical
charts
Entire
pregnancy
Any 99 boys 22.2 Non-asthmatics 370 s 27.8 cRR Z 0.80a NA 40
347 28.8 cRR Z 0.92a NA 35
79 girls 26.6 Asthmatics
with no Rx
191 s 29.3 cRR Z 0.76a NA 35
179 22.9 cRR Z 1.16a NA 28
Bakhireva
et al.
[20]
Cohort Tel.interviews
& medical
charts
Entire
pregnancy
Any 103 3.9 Non-asthmatics 303 5.0 cRR Z 0.78 (>0.05) 17
aOR Z 0.57 0.16, 2.12
Any 103 3.9 Asthmatics
ICS usersb
438 6.2 cRR Z 0.63 0.13, 1.89 20
aOR Z 0.50
Schatz
et al.
[22]
Cohort þ
RCT
Medical
charts & interviews
Entire pregnancy Any 1828 7.1 Asthmatics non-
usersc,d,e
295 7.2 cRR Z 0.99 (>0.05) 39
SABA only: cohort studies
Bracken
et al.
[18]
Cohort Tel.
interviews þ
medical
charts
Entire
pregnancy
Any 401 7.5 Asthmatics and
non-asthmatics
non-usersf
180 7.7 cOR Z 0.97g 0.65, 1.47g 60
aOR Z 1.0h 0.99, 1.01h
Schatz
et al.
[21]
Cohort Daily diary
cards for
medications
completed by
patients. For
outcomes,
data source
not precised
Entire
pregnancy
Anyi NA NA Non-asthmatics NA NA NA (>0.05) __
Schatz
et al.
[23]
Cohort Questionnaire
for patients
identification,
confirmed
clinically þ
Self-diary to
report use of
SABA & medical
records (for
perinatal
outcomes)
Entire
pregnancy
Anyc,j,k 259 1.6 Non-asthmatics 295 1.0 cRR Z 1.6 (>0.05) 9
Asthmatics
non-usersf
101 3.1 cRR Z 0.52 (>0.05) 8
LABA only: cohort studies
Clifton
et al.
[24]
Cohort Medical charts Entire
pregnancy
Salmeteroll 9 22.2 Non-asthmatics 20 10.0 cRR Z 2.2 (>0.05) 9
Asthmatics
fluticasone
users
18 11.1 cRR Z 2.0 (>0.05) 8
Asthmatics
budesonide
users
14 0 __ NA __
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Beta2-agonists and perinatal outcomes 23Among the six studies that evaluated the effect of SABA
separately, two studies used asthmatic women unexposed
to SABA during pregnancy as the reference group [29,37],
and a significant association was found in one study [37]. In
this matched caseecontrol study, Tamasi et al. reported a
significant increased risk of any malformations with
maternal use of fenoterol during the first trimester of
pregnancy (crude OR Z 1.6; 95% CI 1.3, 2.0) [37]. Refer-
ence groups formed by the general population, non-
asthmatic pregnant women, or unspecified reference
groups have been used in four studies [17,36,38,42] and
significant associations were reported in two of these
studies [36,42]. A significant increased risk of any malfor-
mations with the use of epinephrine (SABA) during the first
trimester was reported by the CPP group (RR Z 1.7,
p < 0.05)[42]. Kallen et al. in a retrospective cohort study
using the Swedish Medical Birth Registry reported a slight
increased risk of any malformations with terbutaline use in
the first trimester of pregnancy (aOR Z 1.11; 95% CI 1.04,
1.19) [36].
From the four studies that examined the use of
LABA separately, two used a reference group formed of
asthmatic women unexposed to LABA during pregnancy
[29,37], one used a reference group formed of asthmatic
and non-asthmatic women [38], and the reference
group was the general population in one study [36], Only
one of these studies found a significant result: women
exposed to LABA were found to have an increased risk of
genital malformations (aOR Z 6.84; 95% CI: 2.58, 18.10)
and “other and unspecified malformations” (aOR Z 3.43;
95% CI: 1.39, 8.45) when compared to asthmatic women
unexposed to LABA during pregnancy [29].
The six studies that reported non-significant results for
any congenital malformations and provided enough infor-
mation to calculate the statistical power had a power
ranging from 9% to 100% to detect an effect size of 1.5 with
three studies having a power >80% [29,37,38].
Small for gestational age
Studies that investigated the association between beta2-
agonists use during pregnancy and SGA are presented in
Table 4: three studies examined SABA and/or LABA use
[19,20,22], three studies examined SABA separately
[18,21,23], and two studies examined LABA separately
[18,24]. The three studies that examined the use of SABA
and/or LABA used a reference group of asthmatic pregnant
women unexposed to beta2-agonists during pregnancy
[19,20,22], and none of these studies reported a significant
increased risk of SGA with beta2-agonists use. Among the
three studies that examined SABA separately, only one used
a reference group formed of asthmatic women unexposed
to SABA [23]; and the three studies reported non-significant
associations between SABA exposure and SGA. Among the
two studies that examined LABA separately, one study used
a reference group formed of asthmatic women unexposed
to LABA during pregnancy [24] and both studies reported
non-significant results.
The six studies that reported non-significant results for
SGA and for which we had enough information to calculate
the statistical power had a power ranging from 8% to 60% to
detect an effect size of 1.5.
Table 5 Studies investigating the association between beta2-agonists use during pregnancy and birth weight.
Study ref. Design Source of
data
Exposure
Timing
Users of b2-agonists Non-users of b2-agonists Effect Power (%)
for MD Z
500 g
Type of b2-
agonists
n* Mean birth
weight in
g (SD)
Definition n* Mean birth
weight in
g (SD)
MD in g 95% CI or
(p-value)
SABA and/or LABA use: cohort studies
Clark
et al.
[19]
Cohort Questionnaire
& medical
charts
Entire
pregnancy
Any 99
boys
3545a Non-
asthmatics
370
boys
3320a cMD Z 225b NA __
347
girls
3240a cMD Z 20b NA __
79
girls
3220a Asthmatics
with no Rx
191
boys
3360a cMD Z 185b NA __
179
girls
3260a cMD Z 40b NA __
Bakhireva
et al.
[2]
Cohort Tel. interviews
& medical
charts
Entire
pregnancy
Any 103 3552
(51)
Non-
asthmatics
303 3540 (29) aMD Z 12 (>0.05) 100
Any 103 3552
(51)
Asthmatics
ICS usersc
438 3524 (24) aMD Z 28 (>0.05) 100
Olesen
et al.
[39]
Cohort Registry
& Rx DB
Entire
pregnancy
Any 272 3361.5
(571.3)
Non-users
of any Rxd
8717 3414 (579) aMD Z 45.8 115.1,
23.5
100
Lao et al.
[34]
Cohort Hospitals
DB
Entire
pregnancy
Anye,f 54 3226
(453)
Non-
asthmatics
54 3281 (328) cMD Z 55 (>0.05) 100
SABA only: cohort studies
Schatz
et al.
[23]
Cohort Questionnaire
for patients
identification,
confirmed
clinically þ
Self-Diary to
report use of
SABA & medical
records (for
perinatal
outcomes)
Entire
pregnancy
Anye,g,h 259 3416
(35)i
Non-
asthmatics
295 3477 (32)i cMD Z 61 (>0.05) 100
Asthmatics
non-usersg
101 3361 (68)i cMD Z 55 (>0.05) 100
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LABA only: cohort studies
Clifton
et al.
[24]
Cohort Medical
charts
Entire
pregnancy
Salmeterolj 9 3283
(120.3)i
Non-
asthmatics
20 3423.3
(122)
cMD Z 140.3 (>0.05) 100
Asthmatics
fluticasone
users
18 3441.7
(149.4)
cMD Z 158.7 (>0.05) 100
Asthmatics
budesonide
users
14 3824.6
(100)
cMD Z 541.6 (>0.05) 100
34.8
centile
(9.3)
Non-
asthmatics
20 47.7 (7.4) cMD Z 12.9 (>0.05) 75k
Asthmatics
fluticasone
users
18 53.6 (7.1) cMD Z 18.8 (>0.05) 75k
Asthmatics
budesonide
users
14 74.0 (5.4) cMD Z 39.2 (0.011) NC
The values in bold represent the presence of a statistically significant association.
Women participating in the different studies were asthmatic unless stated otherwise.
* Number of pregnancies unless stated otherwise.
a Median is presented (data on means are unavailable).
b Matching was performed and not considered in crude calculations.
c Women may have concurrently received short-acting beta2-agonists (inhaled or systemic).
d Reference group formed from women who did not purchase any prescription drugs during pregnancy.
e Women may have concurrently received inhaled corticosteroids.
f Women may have concurrently received oral asthma medication.
g Women may have concurrently received asthma controller medications (theophylline or ipratropium).
h Women may have concurrently received asthma controller medications (cromolyn).
i Standard errors of measurements (SEM) are given in parentheses.
j Salmeterol was used in combination with fluticasone propionate.
k Power calculated for a difference in the mean birth weight centile Z 10.
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Birth weight
Studies that investigated the association between beta2-
agonists and birth weight are presented in Table 5: four
examined SABA and/or LABA use [19,20,34,39], one exam-
ined SABA separately [23], and one examined LABA sepa-
rately [24]. Among the four studies that examined SABA
and/or LABA use, two used a reference group formed of
asthmatic women unexposed to beta2-agonists during
pregnancy [19,20]; none of these four studies reported a
significant association between beta2-agonists use during
pregnancy and mean birth weight. The only study that
investigated the association between the use of SABA
separately and birth weight did not find a significant dif-
ference in the mean birth weight between the compared
groups [23]. The only study that examined the association
between the use of LABA separately and birth weight did
not find a significant association with the mean birth
weight, but found a significant decrease in the birth weight
centiles among women exposed to salmeterol when
compared to women exposed to budesonide during preg-
nancy (cMD Z 39.2; p-value: 0.011) [24].
The four studies that reported non-significant results for
birth weight and for which we had enough information to
calculate the statistical power had a power of 100% to
detect a mean difference of 500 g.
Low birth weight
Studies that investigated LBW are presented in Table 6:
three studies examined SABA and/or LABA use [22,33,34],
and two studies examined SABA separately [21,23]. Among
the three studies that examined SABA and/or LABA use, two
of them used a reference group of asthmatic women un-
exposed to beta2-agonists [22,33], and none of these three
studies reported a significant association between beta2-
agonists use during pregnancy and LBW. Among the two
studies that focused on SABA, one used two references
groups, one formed of asthmatic women unexposed to SABA
and one formed of non-asthmatic women [23], and the
other one used a reference group formed of non-asthmatics
[21]. Both studies found no significant association between
SABA use and LBW.
The four studies that reported non-significant results for
LBW and for which we had enough information to calculate
the statistical power had a power ranging from 3% to 67% to
detect an effect size of 1.5.Gestational age and preterm delivery
Gestational age
Studies that investigated the impact of beta2-agonists
on gestational age at birth (in weeks) are presented
in Table 7: three studies investigated the impact of SABA
and/or LABA use [20,34,39] and one study examined
LABA separately [24]. Among the three studies that
examined SABA and/or LABA use, only one used a refer-
ence group formed of asthmatic women (ICS users) [20],
and none of the three studies found a significant associ-
ation between beta2-agonists and gestational age. The
only study that examined LABA separately did not find anysignificant association between LABA use and gestational
age [24].
The four studies that reported non-significant results for
gestational age had a power to detect a mean difference of
one week ranging from 90% to 100%.
Preterm delivery
Studies that investigated the impact of the use of beta2-
agonists on preterm delivery (<37 weeks) are presented in
Table 8: three examined SABA and/or LABA use [22,33,34],
two examined SABA separately [18,23], and one examined
LABA separately [18]. Among the 3 studies that examined
SABA and/or LABA use, 2 studies used a reference group
formed of asthmatic women unexposed to beta2-agonists
during pregnancy [22,33]; none of these three studies re-
ported a significant association between beta2-agonists and
preterm delivery. One of the two studies that examined
SABA separately used a reference group of asthmatic
women unexposed to SABA during pregnancy [23] and both
studies reported non-significant associations with preterm
delivery. Moreover, the study that examined LABA sepa-
rately used a reference group of asthmatic and non-
asthmatic women unexposed to LABA; and did not find a
significant association between LABA and preterm delivery.
The five studies that reported non-significant results for
preterm delivery and for which we had enough information
to calculate the statistical power had a power ranging from
12% to 76% to detect an effect size of 1.5.Discussion
We described 21 studies that investigated the impact of
beta2-agonists use during pregnancy on perinatal outcomes.
Eight studies reported a significant increased risk of
congenital malformations for women exposed to SABA and/
or LABA [31,32,40,41], SABA separately [36,37,40,42], or
LABA separately [29] during pregnancy. On the other hand,
one study found a significant decreased risk of major mal-
formations with high doses of SABA [29]. No significant as-
sociations were reported between SABA and LABA and all
other perinatal outcomes, with the exception of one study
that reported a significant decrease in birth weight centiles
among salmeterol (LABA) users [24]. We observed no
impact of beta2-agonists on the risk of preterm birth
despite that they can inhibit uterine contractions and be
used in IV formulation to control premature labor [44]. This
negative result might be explained by the fact that the drug
profile of inhaled beta2-agonits shows very low detectable
plasma levels with the administration of recommended
doses, and consequently minor e if not negligible e toco-
lytic effect [45e48].
It is worth noting that six of the eight studies reporting
significant increased risk of congenital malformations used
a reference group of non-asthmatic women or a combina-
tion of asthmatic and non-asthmatic women, studies in
which it becomes impossible to separate the effect of the
medication from the disease [31,32,36,40e42]. The other
two studies used a reference group of unexposed asthmatic
women during pregnancy [29,37]. The first reported an
increased risk of any congenital malformations with feno-
terol (SABA) during pregnancy (crude ORZ 1.6; 95% CI: 1.3,
Table 6 Studies investigating the association between beta2-agonists use during pregnancy and low birth weight (<2500 g).
Study ref. Design Source of data Exposure
Timing
Users of b2-agonists Non-users of b2-agonists Effect Power (%)
for RR Z
1.5
Type of b2-
agonists
n* Low birth
weight (%)
Definition n* Low birth
weight (%)
OR or RR 95% CI or
(p-value)
SABA and/or LABA use: cohort studies
Schatz
et al.
[22]
Cohort þ
RCT
Medical charts
& interviews
Entire
pregnancy
Any 1828 13.5 Asthmatics
non-usersa,b,c
295 15.2 cRR Z 0.89 (>0.05) 67
Alexander
et al.
[33]
Cohort Registry
(perinatal DB)
& medical
charts
Not
determined
Any 303 7.9 Non-asthmatics 13,709 5.6 aOR Z 1.4 0.8, 2.2 49
Any 303 7.9 Asthmatics
with no Rx
375 4.9 aOR Z 0.9 0.5, 1.5 24
Any 303 7.9 Asthmatic
steroid usersd
139 5.1 aOR Z 1.0 0.4, 2.5 13
Lao et al.
[34]
Cohort Hospitals DB Entire
pregnancy
Anya 54 5.6 Non-asthmatics 54 1.9 cRR Z 2.9 (>0.05) 3
SABA only: cohort studies
Schatz
et al.
[21]
Cohort Daily diary
cards for
medications
completed by
patients. For
outcomes,
data source
not precised
Entire
pregnancy
Any e NA NA Non-asthmatics NA NA NA (>0.05) __
Schatz
et al.
[23]
Cohort Questionnaire
for patients
identification,
confirmed
clinically þ Self-
Diary to report
use of SABA &
medical records
(for perinatal
outcomes)
Entire
pregnancy
Anya,f,g 259 4.6 Non-asthmatics 295 3.1 cRR Z 1.48 (>0.05) 15
Asthmatics
non-usersd
101 6.0 cRR Z 0.77 (>0.05) 12
Women participating in the different studies were asthmatic unless stated otherwise.
* Number of pregnancies unless stated otherwise.
a Women may have concurrently received inhaled corticosteroids.
b Women may have concurrently received asthma controller medications (leukotriene modifiers).
c Women may have concurrently received systemic corticosteroids (oral or intravenous).
d Women may have concurrently received any other type of asthma medication.
e Women may have received inhaled, oral or injectable beta2-agonists.
f Women may have concurrently received asthma controller medications (theophylline or ipratropium).
g Women may have concurrently received asthma controller medications (cromolyn).
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Table 7 Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Gestational Age (weeks)
Study ref. Design Source of
data
Exposure
Timing
Users of b2-agonists Non-users of b2-agonists Effect Power (%)
for MD Z
1 week
Type of b2-
agonists
n* Gestational
age in weeks
(SD)
Definition n* Gestational
age in weeks
(SD)
MD 95% CI or
(p-value)
SABA and/or LABA use: cohort studies
Bakhireva
et al.
[20]
Cohort Tel. interviews
& medical
charts
Entire
pregnancy
Any 103 39.4 (1.8) Non-asthmatics 303 39.2 (1.5) cMD Z 0.2 (>0.05) 100
Any 103 39.4 (1.8) Asthmatics ICS
usersa
438 39.4 (1.8) cMD Z 0 (>0.05) 100
Olesen
et al.
[39]
Cohort Registry
& Rx DB
Entire
pregnancy
Any 272 276.2 (15 days) non-users of
any Rxb
8717 276.1
(14.5 days)
aMD Z 0.2 2.0, 1.5 100
Lao et al.
[34]
Cohort Hospitals
DB
Entire
pregnancy
Any c 54 39.3 (1.7) Non-asthmatics 54 39.2 (1.5) cMD Z 0.1 (>0.05) 90
LABA only: cohort studies
Clifton
et al.
[24]
Cohort Medical
charts
Entire
pregnancy
Salmeterold 9 39.9 (0.4)e Non-asthmatics 20 40.2 (0.3)e cMD Z 0.3 (>0.05) 100
Asthmatics
fluticasone
users
18 39.6 (0.3)e cMD Z 0.3 (>0.05) 100
Asthmatics
budesonide
users
14 39.7 (0.3)e cMD Z 0.2 (>0.05) 100
Women participating in the different studies were asthmatic unless stated otherwise.
* Number of pregnancies unless stated otherwise.
a Women may have concurrently received short-acting beta2-agonists (inhaled or systemic).
b Reference group formed from women who did not purchase any prescription drugs during pregnancy.
c Women may have concurrently received inhaled corticosteroids.
d Salmeterol was used in combination with fluticasone propionate.
e Standard errors of measurements (SEM) are given in parentheses.
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Table 8 Studies investigating the association between beta2-agonists use during pregnancy and preterm delivery (<37 weeks).
Study ref. Design Source of data Exposure
Timing
Users of b2-agonists Non-users of b2-agonists Effect Power (%)
for RR Z
1.5
Type of b2-
agonists
n* Preterm
delivery
(%)
Definition n* Preterm
delivery
(%)
OR or RR 95% CI or
(p-value)
SABA and/or LABA use: cohort studies
Schatz
et al.
[22]
Cohort þ RCT Medical
charts &
interviews
Entire
pregnancy
Any 1828 15.8 Asthmatics non-
usersa,b,c
295 19.3 cRR Z 0.82 (>0.05) 76
Alexander
et al.
[33]
Cohort Registry
(perinatal DB)
& medical charts
Not
determined
Any 303 6.0 Non-asthmatics 13,709 6.0 aRR Z 1.0 0.5, 1.8 51
Any 303 6.0 Asthmatics with
no Rx
375 5.6 aRR Z 1.0 (0.5, 1.7) 27
Any 303 6.0 Asthmatic steroid
usersd
139 7.7 aOR Z 1.4 0.6, 3.0 18
Lao et al.
[34]
Cohort Hospitals DB Entire
pregnancy
Anya 54 1.9 Non-asthmatics 54 0 e NA e
SABA only: cohort studies
Bracken
et al.
[18]
Cohort Tel. interviews
& medical charts
Entire
pregnancy
Any 529 7.6 Asthmatics and
non-asthmatics
non-usersd
1676 6.7 cOR Z 1.14e 0.79, 1.66e 63
aOR Z 1.01f 1.00, 1.02f
Schatz
et al.
[23]
Cohort Questionnaire
for patients
identification,
confirmed
clinically þ
Self-Diary to
report use of
SABA & medical
records (for
perinatal
outcomes)
Entire
pregnancy
Anya,g,h 259 3.9 Non-asthmatics 295 2.7 cRR Z 1.44 (>0.05) 15
Asthmatics non-
usersd
101 6.0 cRR Z 0.65 (>0.05) 12
(continued on next page)
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30 S. Eltonsy et al.2.0), but no association with other SABA. Self-reported
questionnaires were used to classify cases (n Z 511) and
controls (n Z 757) according to the type of medications
used during pregnancy [37]. Despite adequate statistical
power, this study has other limitations such as non-
adjustment for asthma severity and other confounders as
well as exposure measurement during the entire pregnancy
period [37]. This 60% increased risk is not negligible since
the risk of congenital malformations in the general popu-
lation is believed to be about 3% [43]. The second study
reported a significant increased risk of “major cardiac
malformations” (aOR Z 2.38; 95% CI: 1.11, 5.1), “major
other and unspecified malformations” (aORZ 3.97; 95% CI:
1.29, 12.2) and “any genital malformations” (aOR Z 6.84;
95% CI: 2.58, 18.10) among asthmatic women exposed to
LABA when compared to asthmatic women unexposed to
LABA during the first trimester [29]. Moreover, the study
found that women exposed to SABA at high doses (>10 per
week) were less likely to have a baby with a major mal-
formation. Exposure to medications was measured with
prescription claims collected prospectively and indepen-
dently of the outcome, avoiding recall bias. However,
prescription claims might not reflect exactly the actual
intake of medications [29].
While a comparison group of asthmatic non-users of the
medication under study seems theoretically appropriate, it
should be recognized that asthmatic non-users might have
a milder form of the disease or being under-treated, and
that residual bias by indication might still be present.
Confounding by indication can be reduced in an alternate
way through comparing two similar therapies, i.e. two
treatment regimens with the same indication. SABA and
LABA cannot be included in a head-to-head comparison,
but a comparison between LABA plus ICS in low or medium
doses against high doses of ICS could be informative about
the safety of LABA while minimizing confounding by indi-
cation, and such comparisons should be included in future
studies.
Several other methodological aspects of the studies
included in the review need to be considered. The source of
data varied from one study to the other, being through
medical charts in some, telephone and personal interviews
in others, or registry records and administrative databases,
and different definitions were used to assess asthma ac-
cording to the source of data used. Regarding the exposure
assessment, recall bias might have affected caseecontrol
studies where drug data were collected retrospectively by
interviews or questionnaires causing overestimated effects
[31,32,37,40,41]. On the other hand, a secondary data
source does not suffer this limitation, but could be affected
by non-differential misclassification that underestimates
the true effects [29,33,35,36,39]. The timing of exposure
during pregnancy could influence the results and lead to
variability between studies [49,50]. As for congenital mal-
formations, the most susceptible stage for the embryonic
development is the first trimester, where many teratogenic
agents show their effect [49,50]. On the other hand, the
third trimester of pregnancy might be more relevant for
other measures of fetal growth, such as mean birth weight,
LBW, and SGA since the majority of the fetal growth takes
place during this period [14]. For congenital malformations,
twelve studies examined the use of beta2-agonists during
Beta2-agonists and perinatal outcomes 31the first trimester [17,21,23,29,31,32,35,36,39e42], eight
during the entire pregnancy [19e23,34,35,37], one during
early pregnancy [38], and one did not specify when the
exposure was measured [33]. For SGA, birth weight, and
LBW, nine studies examined the entire pregnancy
[18e24,34,39], and one had an undetermined exposure
period [33]. Regarding gestational age and preterm de-
livery, seven examined the entire pregnancy
[18,20,22e24,34,39], and the timing of the exposure was
not specified in one study [33].
The ascertainment of outcomes varied across studies. In
registry and administrative database studies, diagnostic
codes were used alone to ascertain an infant outcome
[29,33,35]. A potential non-differential information bias
could occur if the accuracy of the information is not high
enough, leading to effect measures closer to the null. Some
studies used patients’ interviews or hospital medical re-
cords to minimize such bias [20e22,31,32,36,39e41].
Another source of bias is the non-response and non-
participation rates which reached high levels (30e40%) in
some studies [31,32,37,40,41]. We can argue that women
exposed to beta2-agonists who choose to participate in a
study were more likely to have a risk factor (i.e. family
history of malformation) compared to non-participants.
This conditional participation could lead to biased results
that overestimate the true effects. In addition, coexisting
morbidity is not uncommon among pregnant asthmatic
women. Pregnant women using anti-asthmatic medications
are often using other types of medications and studies
reporting increased risk of congenital malformations
without adjusting for concomitant drug use or maternal co-
morbidities might have overestimated the effects of beta2-
agonists [31,32,40,41]. Moreover, some of the studies re-
ported only crude results and several of them did not adjust
for the level of asthma severity and control, which have
been shown to be associated with the outcomes under
study [2,4e8].
Furthermore, the negative results obtained in studies
with low statistical power should be interpreted with
caution because they can give a false impression of safety.
Among studies investigating SABA and/or LABA use, only
three among the seven studies had a power of 80% or more
to detect the specified clinically significant effect
[20,34,39]. Moreover, only six studies out of the 12 inves-
tigating SABA separately [23,29,35,37,38,41] and one of the
ten studies investigating LABA separately had a power of
80% or more to detect the specified effect size [24].
This review is limited by the fact that we could not pool
the different study results into a single estimate for each
outcome due to major methodological differences between
the studies. Another limitation of this review is that it
included only studies published in English language, and
excluded studies that do not have comparison groups (i.e.
case-reports, case-series and PEM studies).
The strength of this review lies in the fact that we
included the most relevant studies that provided informa-
tion on the outcomes under study. In addition, we used the
validated and recommended NOS-scale for the quality
assessment of the studies. Another strength of this review is
the post-hoc power calculation that we performed to
identify studies able to detect clinically significant effects.
Compared to previously published reviews on the effect ofbeta2-agonist use during pregnancy [4,14e16,25,26], the
spectrum of perinatal outcomes investigated in the current
review was larger. Previous reviews were also limited by
one or more of the following: investigating only SABA or
only LABA or combining both with other bronchodilators,
screening fewer databases, not assessing the quality of the
studies included, and lastly providing no data on the
studies’ statistical power [4,14e16,25,26].
Beta2-agonists are key medications in the treatment of
asthmatic pregnant women. We found a larger body of
knowledge on salbutamol compared to other SABA, and that
adds to the evidence of its safety. It is difficult to conclude
on the safety of other SABA (i.e. fenoterol and terbutaline),
so we recommend that practitioners prescribe salbutamol
for pregnant women in concordance with the guidelines.
Regarding LABA, there is evidence of specific congenital
malformations increased risk, but it is difficult to interpret
this association as causal because part of this risk might be
attributable to the severity of asthma. Until this observa-
tion is reproduced in other studies, it is difficult to make a
clear recommendation, and the current guidelines should
be followed. Future studies should be large enough to be
able to compare equivalent treatment regimens, or to
compare different molecules of a class in order to minimize
confounding by asthma severity and to identify the safest
treatment options. Future studies might also consider
meta-analysis of drug-specific effects from several well-
conducted studies.Conclusions
In summary, we found 21 studies that examined the effect
of beta2-agonists use during pregnancy on congenital mal-
formations, fetal growth, and prematurity. We found evi-
dence of increased risk of congenital malformations after
pregnancy exposure to fenoterol (SABA) in one study [37]
and LABA in another study [29]. No increased risk was
found for the other outcomes, except a decrease in birth
weight centiles among salmeterol (LABA) users [24].
However, non-significant results should be interpreted
with caution since a large percentage of the negative
studies were under powered to detect clinically significant
effects.
We conclude that other studies on the use of SABA and
LABA during pregnancy are needed to obtain precise esti-
mates of associated risks to rule on their safety profile.Contributors’ statement
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